Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis

J Neurol Neurosurg Psychiatry. 2006 Sep;77(9):1079-82. doi: 10.1136/jnnp.2006.092353.

Abstract

Progressive multifocal leucoencephalopathy (PML), a demyelinating disease caused by the JC virus (JCV), occurs in immunosuppressed patients and carries a poor prognosis. A favourable outcome is reported in two patients with PML and dermatomyositis. Immunosuppressive drugs were stopped in patient 1 but could only be partially tapered in patient 2. The JCV-specific CD8+ T cell response was strong in patient 1 and weak in patient 2. Both were treated with cytosine-arabinoside, and patient 2 was also treated with mirtazapine, a 5HT2A receptor antagonist. Combination of these drugs might be helpful to treat HIV-negative patients with PML.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Antagonists / therapeutic use
  • Cytarabine / therapeutic use
  • Dermatomyositis / complications*
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Leukoencephalopathy, Progressive Multifocal / drug therapy*
  • Leukoencephalopathy, Progressive Multifocal / etiology*
  • Male
  • Mianserin / analogs & derivatives
  • Mianserin / therapeutic use
  • Middle Aged
  • Mirtazapine
  • Treatment Outcome

Substances

  • Adrenergic alpha-Antagonists
  • Immunosuppressive Agents
  • Cytarabine
  • Mianserin
  • Mirtazapine